Why the study?
The incidence of diabetic nephropathy is increasing worldwide, with podocyte injury and loss of slit diaphragm-specific markers representing early pathogenic features.
Does Ang-(1-7) attenuate podocyte injury induced by high glucose in cultured mouse podocytes?
Does Ang-(1-7) attenuate podocyte injury induced by high glucose in cultured mouse podocytes?
Ang-(1-7) protects against high glucose-induced podocyte injury in vitro via the Mas receptor, suggesting a potential therapeutic target for diabetic nephropathy.
Answers are grounded in this paper and cite their sources.
Podocyte protection by Ang-(1-7) in vitro is MasR-dependent; leaves open translation to diabetic nephropathy models or therapy.
Objective: The incidence of diabetic nephropathy (DN) is gradually increasing worldwide. Podocyte injury, such as podocyte apoptosis and loss of the slit diaphragm (SD)-specific markers are early pathogenic features of DN. Materials and The Cell Counting Kit-8 (CCK-8) method and flow cytometry was used to detect podocyte activity and podocyte apoptosis respectively. The expression of angiotensin type 1 receptor (AT1R), Mas receptor (MasR) and podocyte-specific markers were examined by q-PCR and Western blot, respectively. Results: The results showed that the decrease in podocyte activity; the increase in podocyte apoptosis; the decreased mRNA and protein expression of nephrin, podocin, WT-1 and MasR; and the upregulated expression of AT1R induced by HG could be reversed by Ang-(1-7). However, these effects were blocked by A779. The possible mechanisms of the Ang-(1-7)-mediated effect depended on MasR. In addition, the protective effect of Ang-(1-7) on podocyte activity was dose-dependent and most obvious at 10 µM. A779 had the greatest antagonistic action against Ang-(1-7) at a concentration of 10 μM. Conclusion: This study reveals that binding of Ang-(1-7) to its specific receptor MasR may counteract the effects of Ang II mediated by AT1R to significantly attenuate podocyte injury induced by high glucose. Ang-(1-7)/MasR targeting in podocytes may be a therapeutic approach to attenuate renal injury in DN.
No takes yet. Share an insight, caveat, or question.
Lü et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: